Omega-3 Fatty Acid Supplements Do Not Reduce Major Heart Risks: Study

Although omega-3 fatty acid supplements are commonly recommended for individuals at high risk of cardiovascular events, the findings of a new study suggest that they may not actually help avoid heart attacks, strokes or severe chest pains.

In findings published this week in the Journal of the American Medical Association (JAMA), researchers suggest that omega-3 supplements may provide little-to-no-benefit reducing major heart risks.

Researchers conducted a double-blind, randomized, multi-center clinical trial known as the STRENGTH study, which included more than 13,000 patients randomized at 675 academic and community hospitals in 22 countries in North America, Europe, South America, Asia, Australia, New Zealand, and South Africa.

Did You Know?

AT&T Data Breach Impacts Millions of Customers

More than 73 million customers of AT&T may have had their names, addresses, phone numbers, Social Security numbers and other information released on the dark web due to a massive AT&T data breach. Lawsuits are being pursued to obtain financial compensation.

Learn More

In 2017, the American Heart Association issued an advisory that indicated omega-3 fish oil prescribed by doctors may help prevent death from heart disease among those who recently had a heart attack, and may prevent death or hospitalization for patients with heart failure. However, the advisory did not recommend the supplements to the general population.

The new study included statin-treated patients with high cardiovascular risk, high triglycerides and low HDL cholesterol levels. The research focused on examining if adding omega-3 fatty acids would improve cardiovascular outcomes.

Participants were randomized to receive an omega-3 carboxylic acid formulation of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), or corn oil, which was intended as a placebo. EPA and DHA are fatty acids found in cold water fish.

The findings suggested that there was no difference in major adverse cardiovascular events between daily supplementation with omega-3 fatty acids compared with corn oil. Researchers stopped the study early after 1,384 patients experienced no cardiovascular benefit from omega-3 supplementation.

“Among statin-treated patients at high cardiovascular risk, the addition of omega-3 CA, compared with corn oil, to usual background therapies resulted in no significant difference in a composite outcome of major adverse cardiovascular events,” researchers wrote. “These findings do not support use of this omega-3 fatty acid formulation to reduce major adverse cardiovascular events in patients with high cardiovascular risk.”

There was a greater rate of gastrointestinal side events in the omega-3 group. Roughly 25% of participants experienced stomach discomfort or pain. Only 15% of the corn oil group suffered gastrointestinal side effects.

The study showed no benefit in reducing heart problems when supplementing with the omega-3 combination. However, researchers speculate part of the problem may have been the ratio in which the two were given. Perhaps in a different ratio benefits may be seen, as other studies focusing only on either EPA or DHA showed positive benefits.

0 Comments

Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

Uber Driver Sexual Assaults and Misconduct Reports Must Be Disclosed in Lawsuit Discovery
Uber Driver Sexual Assaults and Misconduct Reports Must Be Disclosed in Lawsuit Discovery (Posted today)

A federal magistrate judge is forcing Uber to hand over potentially hundreds of thousands of incident files involving reports of passengers who suffered sexual misconduct or sexual assault at the hands of the rideshare service's drivers.

Abbott May Remove Infant Formula for Preemies Off the Market Due to Similac NEC Lawsuits
Abbott May Remove Infant Formula for Preemies Off the Market Due to Similac NEC Lawsuits (Posted yesterday)

Abbott Laboratories is considering removing Similac infant formula products designed for preterm babies from the market, as it faces hundreds of lawsuits claiming the products increase the risk of necrotizing enterocolitis, which puts newborns at a high risk of permanent injuries and death.

Information About Suboxone Dental Claims To Be Exchanged By Parties in MDL
Information About Suboxone Dental Claims To Be Exchanged By Parties in MDL (Posted 2 days ago)

A federal judge has ordered parties involved in Suboxone dental decay lawsuits to submit proposals for exchanging information that will guide the selection of representative bellwether claims for early test trials.